FDA Determines Regulatory Review Period for AGILI-C Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for AGILI-C, a medical device patent extension application submitted to the US Patent and Trademark Office (USPTO).